Total value is what twelve months of continuous treatment costs, not what month one costs. Four variables decide it: whether the price rises with dose, what the fee actually bundles, what happens at renewal, and whether the medication is a compounded preparation or an FDA-approved brand product. Alternatives to TrimRx sit in three separate categories, and they are not interchangeable.
Three categories, not one shopping list
The first category is other cash-pay compounded platforms. Henry Meds, Mochi Health, Eden, Found, and the weight programs run by Ro and Hims and Hers all operate some version of this: online intake, remote prescriber, compounded semaglutide or tirzepatide by mail, monthly billing. Structures differ sharply on membership fees and dose pricing even when the headline figures look similar.
Another cash-pay option, HealthRX, sits in that same online-intake and mail-delivery mold, listing its GLP-1 medications and the price at each dose on the site so a shopper can run the annual comparison rather than guess at it. Within this group the deciding factor is rarely the name at the top of the page; it is whether the monthly figure holds as the dose climbs, which is where two similar-looking programs part company.
The second category is manufacturer self-pay channels for the brand drugs. Eli Lilly sells Zepbound vials directly through LillyDirect, and Novo Nordisk sells Wegovy through NovoCare Pharmacy. These dispense FDA-approved products with approved labeling, at prices well below list but generally above compounded platforms. Published rates change periodically, so the figure on the manufacturer page at the moment you order is the only one worth planning around.
The third category is insurance-routed care through a primary care clinician or a covered obesity specialist. Where a plan covers anti-obesity medication, the out-of-pocket cost can fall below any cash option. Coverage remains uneven, and Medicare Part D rules have historically excluded drugs used for weight loss alone, which is why so many people end up in the cash market at all.
What separates the compounded platforms from each other
Since they all dispense the same two molecules, medication is not the differentiator. Pricing architecture is. Some programs hold one price regardless of strength. Others tier the price by dose, which matters because every GLP-1 regimen escalates over months, so a low entry price at the starting strength can be a poor guide to the twelfth month.
| Category | Representative options | Typical cost structure | What drives the annual total |
|---|---|---|---|
| Cash-pay compounded | TrimRx, Henry Meds, Mochi Health, Eden, Ro, Hims and Hers | Monthly fee, sometimes plus membership | Whether price scales with dose; prepaid plan length |
| Manufacturer self-pay | LillyDirect (Zepbound), NovoCare (Wegovy) | Per-fill vial pricing, no membership | Dose tier and program terms at time of order |
| Insurance-routed | Primary care, obesity medicine clinics | Copay or coinsurance plus visit costs | Formulary status, prior authorization, plan year changes |
The first month is the least informative number
Promotional entry rates are standard across this market, and they are frequently tied to a prepaid multi-month commitment. Two programs quoting similar introductory figures can diverge by hundreds of dollars a year once the promotional period ends, the dose rises, and any membership fee is added back.
A workable method is to price the same twelve months at every provider on the list. Take the strength you would realistically be on by month six, add every recurring fee, add lab work if it is not bundled, add shipping if it is separate, then multiply. That number is comparable across providers. A headline price is not.
Published pricing is the input that makes this arithmetic possible, and providers vary in how much of it they post. Comparison write-ups can help assemble the list of variables, although many are published by competing platforms rather than neutral reviewers. A TrimRx breakdown hosted at formblends.com is one example of a competitor-authored side-by-side, and pages of that kind are useful for the questions they surface as long as each figure is verified on the provider’s own order page before it goes into the calculation.
Compounded and brand are different regulatory products
This distinction is often flattened in price comparisons, and it should not be. Compounded semaglutide and compounded tirzepatide are not FDA-approved. The agency has not reviewed those preparations for safety, effectiveness, or manufacturing quality, and the FDA has published specific concerns about unapproved GLP-1 products sold for weight loss, including dosing errors and unverified sourcing.
That does not make compounded care illegitimate. Licensed prescribers and licensed pharmacies operate in a defined legal framework, and for people priced out of the brand products it may be the only realistic route. It does mean a price gap between a compounded program and a manufacturer channel is not a pure discount on the same item. Part of the gap is a difference in what has been reviewed.
What the clinical evidence can and cannot settle
Trial data speaks to molecules, not to vendors. Semaglutide in its registration trial produced roughly 15 percent mean body weight reduction over 68 weeks. Tirzepatide in its own separate trial produced roughly 21 percent at the highest dose over 72 weeks. Those were different studies with different populations, so the figures indicate a direction rather than a measured margin between the two drugs. A later randomized comparison of the two molecules has since reported greater average reduction with tirzepatide.
None of that tells you which provider to use. What it does tell you is that tirzepatide programs generally cost more than semaglutide programs for a reason, and that switching platforms mid-course to chase a lower price restarts nothing clinically as long as the same molecule and strength continue without a supply gap.
Frequently asked questions
Is the cheapest compounded platform usually the best value?
Rarely, unless its price holds at higher strengths. Programs that tier by dose can start below a flat-rate competitor and finish well above it by month twelve. Value is decided by the dose ladder and the renewal terms, not by the entry rate advertised on the landing page.
Are the brand self-pay programs worth the extra cost?
For some people, yes. They dispense FDA-approved products with approved labeling, a known manufacturer, and pharmacy dispensing records that transfer cleanly to other clinicians. Whether that premium is worth paying depends on budget and on how much weight you place on approval status.
Does insurance ever cover any of this?
Commercial coverage for anti-obesity medication exists but is inconsistent, and it typically requires prior authorization and documented criteria. Medicare drug coverage has historically excluded agents used for weight loss alone. Checking the plan formulary before assuming cash pay is the cheaper route takes one call.
Can you move from one provider to another mid-treatment?
Generally yes, since a new prescriber issues a new prescription after their own intake. The practical risk is a supply gap during the transfer, which interrupts an escalation schedule. Starting the second intake before the current supply runs out avoids most of that problem.
Do lab tests change the comparison?
They can. Some programs include baseline labs, some require them at your expense, and some do not ask for any. A program that skips labs is not automatically cheaper, since the testing may still be clinically warranted and simply moves onto a different bill.
